JP2007504280A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504280A5
JP2007504280A5 JP2006532897A JP2006532897A JP2007504280A5 JP 2007504280 A5 JP2007504280 A5 JP 2007504280A5 JP 2006532897 A JP2006532897 A JP 2006532897A JP 2006532897 A JP2006532897 A JP 2006532897A JP 2007504280 A5 JP2007504280 A5 JP 2007504280A5
Authority
JP
Japan
Prior art keywords
antibody
ovr110
cells
cancer
pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006532897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504280A (ja
JP4884224B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/014490 external-priority patent/WO2004101756A2/en
Publication of JP2007504280A publication Critical patent/JP2007504280A/ja
Publication of JP2007504280A5 publication Critical patent/JP2007504280A5/ja
Application granted granted Critical
Publication of JP4884224B2 publication Critical patent/JP4884224B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006532897A 2003-05-09 2004-05-10 Ｏｖｒ１１０抗体組成物および使用方法 Expired - Fee Related JP4884224B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46955503P 2003-05-09 2003-05-09
US60/469,555 2003-05-09
US55295904P 2004-03-12 2004-03-12
US60/552,959 2004-03-12
US55646404P 2004-03-25 2004-03-25
US60/556,464 2004-03-25
PCT/US2004/014490 WO2004101756A2 (en) 2003-05-09 2004-05-10 Ovr110 antibody compositions and methods of use

Publications (3)

Publication Number Publication Date
JP2007504280A JP2007504280A (ja) 2007-03-01
JP2007504280A5 true JP2007504280A5 (enExample) 2007-11-22
JP4884224B2 JP4884224B2 (ja) 2012-02-29

Family

ID=33458763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532897A Expired - Fee Related JP4884224B2 (ja) 2003-05-09 2004-05-10 Ｏｖｒ１１０抗体組成物および使用方法

Country Status (9)

Country Link
US (2) US7619068B2 (enExample)
EP (1) EP1633784B1 (enExample)
JP (1) JP4884224B2 (enExample)
AT (1) ATE516047T1 (enExample)
AU (1) AU2004239301B2 (enExample)
CA (1) CA2525899C (enExample)
DK (1) DK1633784T3 (enExample)
IL (1) IL171797A (enExample)
WO (1) WO2004101756A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
EP1539218A4 (en) * 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
US7153950B2 (en) 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
US7619068B2 (en) * 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2006053110A2 (en) 2004-11-10 2006-05-18 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP1812465B1 (en) * 2004-11-12 2016-09-07 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
DK1841793T3 (da) * 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP1868647A4 (en) * 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
US8609816B2 (en) * 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
US20070286865A1 (en) * 2006-01-04 2007-12-13 Richard Moore Use of HE4 and other biochemical markers for assessment of ovarian cancers
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
RU2691698C2 (ru) 2012-02-24 2019-06-17 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против sez6 и способы их применения
CA2878494A1 (en) * 2012-07-10 2014-01-16 Baxter Healthcare S.A. Anti-mif immunohistochemistry
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
MX2015010777A (es) * 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
SMT202100146T1 (it) 2014-04-30 2021-05-07 Pfizer Coniugati di anticorpo anti-ptk7-farmaco
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
EP3454864A4 (en) 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Novel anti-bmpr1b antibodies and methods of use
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN116172059A (zh) * 2021-11-29 2023-05-30 内蒙古伊利实业集团股份有限公司 青苹果微胶囊、包含其的发酵乳及发酵乳饮料和制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20050229272A1 (en) 1999-12-30 2005-10-13 Monica Driscoll Compositions and methods for gene silencing
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001273194A1 (en) * 2000-06-30 2002-01-14 Amgen Inc. B7-Like Molecules and Uses Thereof
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7619068B2 (en) * 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
AU2007325283B2 (en) * 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use

Similar Documents

Publication Publication Date Title
Sun et al. CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties
Cheng et al. MORAb-202, an antibody–drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity
JP6491701B2 (ja) 新規モジュレーターと使用の方法
JP2021151263A (ja) シアリル−Ｌｅｗｉｓ ａに対するヒト抗体をコードする核酸
JP2010510809A5 (enExample)
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2005538701A5 (enExample)
JP2008546780A5 (enExample)
JP2012100677A5 (enExample)
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
DK2623594T5 (en) Antibody against human prostaglandin E2 receptor EP4
CA3289997A1 (en) Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
NZ283366A (en) Monoclonal antibodies recognizing tie receptors (receptor tyrosine kinase) and their use
RU2015108348A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2006507013A5 (enExample)
CA2595610A1 (en) Antibodies directed to angiopoietin-2 and uses thereof
TW201800421A (zh) 新穎調節劑及使用方法
JP2010537671A5 (enExample)
JP2021528047A5 (enExample)
JP2008537673A5 (enExample)
JP2014515600A5 (enExample)
JP2007516232A5 (enExample)
JP7835441B2 (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
JP2007516226A5 (enExample)
Zingg et al. Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors